James Raymond Grimsley Iii, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 605 S Avenue F, Knox City, TX 79529 Phone: 940-276-1044 |
News Archive
Sleep disorders are associated with significantly higher rates of health care utilization, conservatively placing an additional $94.9 billion in costs each year to the United States health care system, according to a new study from researchers at Mass Eye and Ear, a member hospital of Mass General Brigham.
NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Veterans Affairs for a clinical trial to evaluate the benefits of non-invasive, external Trigeminal Nerve Stimulation (eTNS) for patients with traumatic brain injury (TBI) in a Phase I clinical trial.
Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.
Vicon, a world leader in motion capture for the life sciences industry, today announces the launch of its latest vision paper highlighting some of the key trends and developments that will determine the future of motion capture technology in clinical settings within the next five years.
› Verified 9 days ago